Ajanta Pharma shares jump nearly 4% on USFDA nod for drug

The US health regulator, gives final approval for its generic version of acute migraine pain relief drug

Shares of Ajanta Pharma rose nearly 4 per cent on Tuesday after it received final approval for its generic version of acute migraine pain relief drug almotriptan malate tablets from the US health regulator.

The stock went up 3.69 per cent to Rs 1,448.80 on BSE.

Read more from our special coverage on "AJANTA PHARMA"

• Ajanta Pharma gains on USFDA nod for Almotriptan Malate tablets

On NSE, it surged 3.81 per cent to Rs 1,450.

The approval by the US Food and Drug Administration (USFDA) is for multiple strengths of 6.25mg and 12.5mg of the generic version of Janssen Pharmaceuticals' Axert tablets, Ajanta Pharma said in a BSE filing on Monday.

Ajanta Pharma USA Inc, a wholly-owned subsidiary of the company, is scheduled to launch the almotriptan malate tablets in the US shortly, it said.

Almotriptan tablets is a part of an "ever growing portfolio" that the company has developed for the US market, the company added.